ARDS Clinical Trial
Official title:
Assessment of the Inflammatory Response Associated With the Increase of Transpulmonary Pressure in Ipoxiemic Patients During Assisted Mechanical Ventilation
The present pilot randomized controlled clinical trial will test the hypothesis that in patients with ARDS, fixing ventilator settings to the conventional protective ventilatory strategy (VT 6 ml/kg ideal body weight and Pplat ≤ 30 cmH2O, PEEP according the PEEP/FiO2 table), control modes of mechanical ventilation will be associated to a concentration of pulmonary and systemic inflammatory mediators lower than the concentration of inflammatory mediators observed during assisted modes of mechanical ventilation.
All patients will be treated according to the sedation protocols and standards of care.
Sedation will be guaranteed by continuous infusion of Propofol 2-4 ml / Kg / h, Remifentanil
0.05-0.1 mcg / Kg / min to obtain a RASS scale level of -5 of the RASS. Mio-resolution
eventually obtained by a loading dose of 15 mg e.v. followed by a continuous infusion of 37.5
mg / h of besylated Cisatracury, will be reserved for patients with P/F <150.
During a 48 hrs pre-randomization period, control mechanical ventilation will be set with a
Tidal Volume (VT) of 6 ml / kg (for ideal weight) and a Pplat limited to 30 cm H2O;
inspiratory flow 50-70 l / min with end-of-breath pause of 0.2-0.5 sec, ratio I: E from 1: 1
to 1: 3, respiratory frequency of 20-35 steps to maintain 7.3 <pH <7.5. If the pH is <7.30
the respiratory frequency will increase up to 35 / min; If the pH is> 7.5, the respiratory
rate will be progressively reduced to the target pH range. FiO2 and The PEEP will be set
according to the ARDSnet table (33)
After 48 hours, the patient will be randomized through one of the following two groups:
Control Mechanical ventilation (CMV): patient's spontaneous activity will be shut done by
sedation and/or respiratory muscles paralysis. Volume (during volume control) or pressure
(during pressure control), PEEP, FiO2 and respiratory rate will be regulated according the
ARDSnet protocol (33).
Pressure Support Ventilation (PSV): patient's spontaneous activity will maintained and
sedation will be maintained at a level of Richmond Assessment Sedation Scale (RASS) between
-2 and -3. The level of pressure support (including PEEP) will be limited to ≤ 30 cmH2O; the
pressure support level will ensure a tidal volume of 6 ml / Kg ideal body weight. PEEP, FiO2
and respiratory rate will be regulated according the ARDSnet protocol (33)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04435613 -
Clinical and Physiological Assessment of a Nearly Ultra-protective Lung Ventilation Strategy: A Quasi-experimental Preliminary Study in ARDS Patients
|
N/A | |
Enrolling by invitation |
NCT05020210 -
Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
|
||
Completed |
NCT04468971 -
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
|
Phase 1 | |
Completed |
NCT04505592 -
Tenecteplase in Patients With COVID-19
|
Phase 2 | |
Completed |
NCT04493242 -
Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS
|
Phase 2 | |
Withdrawn |
NCT04909879 -
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
|
Phase 2 | |
Completed |
NCT02265198 -
Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome
|
N/A | |
Completed |
NCT01949272 -
Optimization of PEEP for Alveolar Recruitment in ARDS
|
N/A | |
Not yet recruiting |
NCT01668368 -
Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance
|
N/A | |
Completed |
NCT01881061 -
Lung Sonography in Patients With Acute Respiratory Distress Syndrome in Intensive Care Unit
|
N/A | |
Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
Completed |
NCT05035589 -
The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
|
||
Recruiting |
NCT04764032 -
Right Ventricular Dysfunction in Ventilated Patients With COVID-19
|
||
Completed |
NCT04556513 -
Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status
|
||
Recruiting |
NCT06036056 -
NMR Based Metabolomics Kinetics in ARDS Patients
|
||
Recruiting |
NCT04503876 -
Effects of End-expiratory Positive Pressure Optimization in Intubated Patients With Healthy Lung or Acute Respiratory Distress Syndrome
|
N/A | |
Recruiting |
NCT04643691 -
Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS
|
Phase 2 | |
Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
Not yet recruiting |
NCT05341687 -
Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
|
||
Recruiting |
NCT05056090 -
Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome.
|
N/A |